Apple Tree Responses to Deficit Irrigation Combined with Periodic Applications of Particle Film or Abscisic Acid

The objective of this study was to determine if the application of two antitranspirant compounds would moderate water deficit stress effects on physiological responses of “Granny Smith”, “Royal Gala” and “Golden Delicious” apple (Malus domestica Borkh.) trees on MM106 rootstock that occur during deficit irrigation. Uniform trees were grown in pots under water supply regimes of 30%, 60%, and 80% depletion of available water (DAW) before irrigation to runoff and received applications of kaolin particle film (PF) or abscisic acid (ABA) at 0, 30 and 60 days. At 120 days, genotype and deficit irrigation affected nearly all leaf traits, but antitranspirant treatment had no significant effects. As the % DAW increased, the net photosynthetic rate (Pn), transpiration rate (T), stomatal conductance, leaf water and pressure potential, variable-to-maximal chlorophyll fluorescence, leaf number, and leaf N, P and K contents were reduced. A significant genotype by deficit irrigation interaction was evident on T, water use efficiency (WUE), and leaf osmotic pressure potential. A significant deficit irrigation by antitranspirant interaction was evident on only leaf Pn, with PF and ABA reducing it at 30% DAW and only PF reducing it at 80% DAW. However, the periodic use of PF or ABA during deficit irrigation did not alleviate most physiological effects of water deficit stress due to deficit irrigation

IN-VITRO BIOEQUIVALENCE STUDY FOR MARKETED INNOVATOR AND THREE BRANDS LOCAL MANUFACTURING CIPROFLOXACIN HYDROCHLORIDE TABLETS IN YEMEN

Background and objective: This study is focused to evaluate the in vitro bioequivalence of three brands of ciprofloxacin 500mg tablets from local producer and marketing in Yemen, with innovator brand using in vitro dissolution study under biowaiver conditions by UV spectrophotometer. Method: The Dissolution profile has been evaluated by testing in dissolution media were USP buffer solution at pH 1.2 (hydrochloric acid solution), pH 4.5 (acetate buffer solution) and pH 6.8 (phosphate buffer solution). Also, further general quality assessment tests of these tablets like weight variation, disintegration time hardness, friability and assay test were accomplished according to proven methods. Results: All brands conformed to the official specification for uniformity of weight, friability and disintegration time. Content uniformity of chosen tablets shown that all samples contained over 99% (w/w) of labeled chemical content. The profile dissolution finding of all the tablets formulation and the innovator brand were further analyzed with difference factor (f1) and similarity factor (f2). Conclusion: These results indicated that the generic Cipro® (C) tablets included in this study was bioequivalent with the chosen innovator brand at 0.2N hydrochloric acid solution, pH 1.2 and the other generic brands bioequivalent with the chosen innovator brand at this medium. Also, the results showed that the three generic ciprofloxacin tablets involved in this study were bioequivalent with the selected innovator brand at pH 4.5 and pH 6.8.                           Peer Review History: Received: 1 September 2022; Revised: 12 October; Accepted: 3 November, Available online: 15 November 2022 Academic Editor: Dr. Amany Mohamed Alboghdadly, Princess Nourah bint abdulrahman university, Riyadh, [email protected] Received file:                             Reviewer's Comments: Average Peer review marks at initial stage: 6.5/10 Average Peer review marks at publication stage: 7.0/10 Reviewers: Dr. Evren Alğin Yapar, Turkish Medicines and Medical Devices Agency, Turkiye, [email protected] Dr. George Zhu, Tehran University of Medical Sciences, Tehran, Iran, [email protected] Similar Articles:   QUALITY CONTROL ASSESSMENT OF DIFFERENT BRANDS OF CIPROFLOXACIN 500 MG TABLETS IN YEME

A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants

Since the first case of Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, SARS-CoV-2 infection has affected many individuals worldwide. Eventually, some highly infectious mutants—caused by frequent genetic recombination—have been reported for SARS-CoV-2 that can potentially escape from the immune responses and induce long-term immunity, linked with a high mortality rate. In addition, several reports stated that vaccines designed for the SARS-CoV-2 wild-type variant have mixed responses against the variants of concern (VOCs) and variants of interest (VOIs) in the human population. These results advocate the designing and development of a panvaccine with the potential to neutralize all the possible emerging variants of SARS-CoV-2. In this context, recent discoveries suggest the design of SARS-CoV-2 panvaccines using nanotechnology, siRNA, antibodies or CRISPR-Cas platforms. Thereof, the present comprehensive review summarizes the current vaccine design approaches against SARS-CoV-2 infection, the role of genetic mutations in the emergence of new viral variants, the efficacy of existing vaccines in limiting the infection of emerging SARS-CoV-2 variants, and efforts or challenges in designing SARS panvaccines

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

Background: Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods: The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18-49, 50-69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results: NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case 115 007, worst case 20 177) COVID-19-related deaths in 1 year. Conclusion: As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population